William Blair Investment Management LLC bought a new position in shares of Stevanato Group S.p.A. (NYSE:STVN - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 47,065 shares of the company's stock, valued at approximately $1,026,000.
Several other hedge funds have also recently added to or reduced their stakes in STVN. TimesSquare Capital Management LLC lifted its position in shares of Stevanato Group by 114.6% during the 4th quarter. TimesSquare Capital Management LLC now owns 3,288,529 shares of the company's stock valued at $71,657,000 after acquiring an additional 1,756,100 shares during the last quarter. Jennison Associates LLC purchased a new stake in shares of Stevanato Group during the fourth quarter valued at $20,239,000. Mutual of America Capital Management LLC acquired a new position in shares of Stevanato Group in the 4th quarter valued at $13,848,000. New York State Common Retirement Fund purchased a new position in Stevanato Group in the 4th quarter worth about $8,879,000. Finally, Conestoga Capital Advisors LLC increased its stake in Stevanato Group by 5.3% in the 4th quarter. Conestoga Capital Advisors LLC now owns 8,082,996 shares of the company's stock worth $176,128,000 after purchasing an additional 407,086 shares in the last quarter.
Stevanato Group Stock Performance
STVN stock traded down €0.17 ($0.18) during midday trading on Monday, hitting €22.34 ($24.28). 217,356 shares of the company traded hands, compared to its average volume of 347,708. The business has a 50 day simple moving average of €21.03 and a 200-day simple moving average of €20.59. The company has a quick ratio of 1.21, a current ratio of 1.81 and a debt-to-equity ratio of 0.22. Stevanato Group S.p.A. has a twelve month low of €16.56 ($18.00) and a twelve month high of €33.49 ($36.40). The stock has a market capitalization of $6.77 billion, a price-to-earnings ratio of 47.53, a price-to-earnings-growth ratio of 7.18 and a beta of 0.60.
Stevanato Group (NYSE:STVN - Get Free Report) last posted its earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of €0.20 ($0.22). The business had revenue of €352.68 million for the quarter, compared to analyst estimates of €346.26 million. Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. As a group, equities research analysts predict that Stevanato Group S.p.A. will post 0.5 earnings per share for the current year.
Analysts Set New Price Targets
STVN has been the topic of a number of research analyst reports. Wolfe Research started coverage on shares of Stevanato Group in a research report on Friday, December 13th. They set an "outperform" rating and a $28.00 price objective on the stock. Morgan Stanley reaffirmed an "equal weight" rating and set a $23.00 price target (down from $24.00) on shares of Stevanato Group in a research note on Tuesday, December 3rd. William Blair reissued an "outperform" rating on shares of Stevanato Group in a research note on Friday, March 7th. Bank of America raised their price objective on shares of Stevanato Group from $24.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, December 13th. Finally, UBS Group decreased their target price on shares of Stevanato Group from $24.00 to $23.50 and set a "neutral" rating for the company in a research report on Friday, March 7th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Stevanato Group has an average rating of "Moderate Buy" and a consensus price target of €27.75 ($30.16).
Check Out Our Latest Research Report on Stevanato Group
About Stevanato Group
(
Free Report)
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.
Featured Articles
Before you consider Stevanato Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stevanato Group wasn't on the list.
While Stevanato Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
